167 related articles for article (PubMed ID: 29721203)
1. Patient derived xenografts (PDX) predict an effective heparanase-based therapy for lung cancer.
Katz A; Barash U; Boyango I; Feld S; Zohar Y; Hammond E; Ilan N; Kremer R; Vlodavsky I
Oncotarget; 2018 Apr; 9(27):19294-19306. PubMed ID: 29721203
[TBL] [Abstract][Full Text] [Related]
2. Heparanase inhibitors restrain mesothelioma.
Lapidot M; Barash U; Vlodavsky I; Pass H
Oncotarget; 2018 Dec; 9(96):36830-36832. PubMed ID: 30627323
[TBL] [Abstract][Full Text] [Related]
3. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
Hammond E; Brandt R; Dredge K
PLoS One; 2012; 7(12):e52175. PubMed ID: 23300607
[TBL] [Abstract][Full Text] [Related]
4. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
5. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.
Weissmann M; Bhattacharya U; Feld S; Hammond E; Ilan N; Vlodavsky I
Matrix Biol; 2019 Apr; 77():58-72. PubMed ID: 30096360
[TBL] [Abstract][Full Text] [Related]
6. Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression.
Vlodavsky I; Gross-Cohen M; Weissmann M; Ilan N; Sanderson RD
Trends Biochem Sci; 2018 Jan; 43(1):18-31. PubMed ID: 29162390
[TBL] [Abstract][Full Text] [Related]
7. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.
Dredge K; Hammond E; Handley P; Gonda TJ; Smith MT; Vincent C; Brandt R; Ferro V; Bytheway I
Br J Cancer; 2011 Feb; 104(4):635-42. PubMed ID: 21285983
[TBL] [Abstract][Full Text] [Related]
8. Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance.
Lanzi C; Zaffaroni N; Cassinelli G
Curr Med Chem; 2017; 24(26):2860-2886. PubMed ID: 28215163
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory Activities of the Heparan Sulfate Mimetic PG545.
Bendersky V; Yang Y; Brennan TV
Adv Exp Med Biol; 2020; 1221():461-470. PubMed ID: 32274722
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.
Barash U; Lapidot M; Zohar Y; Loomis C; Moreira A; Feld S; Goparaju C; Yang H; Hammond E; Zhang G; Li JP; Ilan N; Nagler A; Pass HI; Vlodavsky I
J Natl Cancer Inst; 2018 Oct; 110(10):1102-1114. PubMed ID: 29579286
[TBL] [Abstract][Full Text] [Related]
11. Structural Insights into Pixatimod (PG545) Inhibition of Heparanase, a Key Enzyme in Cancer and Viral Infections.
Chhabra M; Wilson JC; Wu L; Davies GJ; Gandhi NS; Ferro V
Chemistry; 2022 Feb; 28(11):e202104222. PubMed ID: 34981584
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues.
Hammond E; Handley P; Dredge K; Bytheway I
FEBS Open Bio; 2013; 3():346-51. PubMed ID: 24251094
[TBL] [Abstract][Full Text] [Related]
13. The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression.
Singh P; Blatt A; Feld S; Zohar Y; Saadi E; Barki-Harrington L; Hammond E; Ilan N; Vlodavsky I; Chowers Y; Half E
Neoplasia; 2017 Mar; 19(3):175-184. PubMed ID: 28147305
[TBL] [Abstract][Full Text] [Related]
14. New Heparanase-Inhibiting Triazolo-Thiadiazoles Attenuate Primary Tumor Growth and Metastasis.
Barash U; Rangappa S; Mohan CD; Vishwanath D; Boyango I; Basappa B; Vlodavsky I; Rangappa KS
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34199150
[TBL] [Abstract][Full Text] [Related]
15. Heparanase 2 Attenuates Head and Neck Tumor Vascularity and Growth.
Gross-Cohen M; Feld S; Doweck I; Neufeld G; Hasson P; Arvatz G; Barash U; Naroditsky I; Ilan N; Vlodavsky I
Cancer Res; 2016 May; 76(9):2791-801. PubMed ID: 27013193
[TBL] [Abstract][Full Text] [Related]
16. Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation.
Brennan TV; Lin L; Brandstadter JD; Rendell VR; Dredge K; Huang X; Yang Y
J Clin Invest; 2016 Jan; 126(1):207-19. PubMed ID: 26649979
[TBL] [Abstract][Full Text] [Related]
17. Involvement of heparanase in the pathogenesis of acute kidney injury: nephroprotective effect of PG545.
Abassi Z; Hamoud S; Hassan A; Khamaysi I; Nativ O; Heyman SN; Muhammad RS; Ilan N; Singh P; Hammond E; Zaza G; Lupo A; Onisto M; Bellin G; Masola V; Vlodavsky I; Gambaro G
Oncotarget; 2017 May; 8(21):34191-34204. PubMed ID: 28388547
[TBL] [Abstract][Full Text] [Related]
18. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
Winterhoff B; Freyer L; Hammond E; Giri S; Mondal S; Roy D; Teoman A; Mullany SA; Hoffmann R; von Bismarck A; Chien J; Block MS; Millward M; Bampton D; Dredge K; Shridhar V
Eur J Cancer; 2015 May; 51(7):879-892. PubMed ID: 25754234
[TBL] [Abstract][Full Text] [Related]
19. Heparanase Inhibition by Pixatimod (PG545): Basic Aspects and Future Perspectives.
Hammond E; Dredge K
Adv Exp Med Biol; 2020; 1221():539-565. PubMed ID: 32274726
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
